Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Practice Resource Library
Integrating Biomarker and Genetic Testing for HRR Mutations into Prostate Cancer Management
Testing for homologous recombination repair mutations (HRRm) for prostate cancer patients can provide insights that may guide targeted treatment decisions, inform prognosis and provide familial risk implications for family members.
Recognizing the value of genetic and biomarker testing in the management of prostate cancer, the American Urological Association (AUA) collaborated with Pfizer Oncology to assess current practice patterns pertaining to germline and somatic HRRm testing for prostate cancer and to identify existing practices to improve patient care. This was accomplished by developing and fielding a survey to AUA members in the United States to assess current practices and challenges related to germline and somatic HRRm testing for prostate cancer, and developing an infographic to display key results of the survey. Additionally, AUA staff conducted in-depth qualitative interviews with representatives from three practices who manage prostate cancer patients. From these interviews, several key findings emerged for practices for integrating HRRm testing into the management of prostate cancer patients.
While there is no one-size-fits-all model for every program, this resource offers valuable insights for those looking to efficiently and effectively integrate biomarker and genetic testing to provide personalized care for prostate cancer patients.
advertisement
advertisement